Factor | 1 point | 2 points | 3 points |
 Total bilirubin (μmol/L) | <34 | 34–50 | >50 |
 Serum albumin (g/L) | >35 | 28–35 | <28 |
 PT INR | <1.7 | 1.71–2.30 | >2.30 |
 Ascites | None | Mild to moderate | Severe/refractory |
 Hepatic encephalopathy | None | Grade I–II (or suppressed with medication) | Grade III–IV (or refractory) |
Child–Pugh class | Class A | Class B | Class C |
 Total points | 5–6 | 7–9 | 10–15 |
Recommendation in patients with AML | The recommended dose is 7.5Â mg daily | The recommended dose is 5Â mg daily | Everolimus is only recommended if the desired benefit outweighs the risk; a dose of 2.5Â mg daily must not be exceeded |
Recommendation in patients with SEGA | 75% of the recommended starting dose, calculation based on BSA (rounded to the nearest strength) | 25% of the recommended starting dose, calculation based on BSA (rounded to the nearest strength) | Everolimus is not recommended |